When infective endocarditis is caused by penicillin-susceptible oral streptococci or the Streptococcus gallolyticus group, the susceptibility profile opens well-defined antibiotic options with clear criteria for safe transition to outpatient care.
The causative organism is a penicillin-susceptible oral streptococcus or S. gallolyticus group. The treatment strategy — including agent choice and duration — differs depending on whether a native or prosthetic valve is affected, and on individual patient factors.
Beta-lactam antibiotic therapy is the cornerstone of management for this susceptible organism. The full protocol specifies which agents apply, how duration is adjusted for native versus prosthetic valve involvement, and the conditions under which an abbreviated combination regimen is appropriate for selected patients.
The aim is clinical stability allowing transition to outpatient antibiotic therapy (OPAT) after 10–14 days of treatment: sustained absence of fever, and normalisation of inflammatory markers including CRP and leukocyte count.
DOI: 10.1093/eurheartj/ehad193
In patients with IE due to oral streptococci and S. gallolyticus group, penicillin G, amoxicillin, or ceftriaxone are recommended for 4 (in NVE) or 6 weeks (in PVE), using the following doses:
2-week treatment with penicillin G, amoxicillin, ceftriaxone combined with gentamicin is recommended only for the treatment of non-complicated NVE due to oral streptococci and S. gallolyticus in patients with normal renal function using the following doses:
After 10–14 days of therapy, OPAT or outpatient oral antibiotic therapy should be considered.
Satisfying response to treatment: no fever >2 days, CRP <25% of max measured value or <20 mg/L and leukocytes <15 × 10⁹/L